KTP laser destruction of dysplasia and early cancer in columnar-lined Barrett's esophagus - PubMed (original) (raw)
Clinical Trial
KTP laser destruction of dysplasia and early cancer in columnar-lined Barrett's esophagus
L Gossner et al. Gastrointest Endosc. 1999 Jan.
Abstract
Background: The rising incidence of esophageal adenocarcinoma in western countries requires a new strategy in the management of dysplasia in Barrett's esophagus. Esophagectomy, which has high morbidity and mortality rates, has been recommended to treat patients with severe dysplasia. Strictly superficial laser coagulation with tissue ablation therefore is a desirable option for the management of dysplasia in Barrett's esophagus because the tissue to be ablated is only about 2 mm thick. Potassium-titanyl-phosphate (KTP) laser light with a wavelength of 532 nm is preferentially absorbed by hemoglobin and therefore combines excellent coagulation with limited tissue penetration. We report first clinical results with KTP laser superficial vaporization of dysplasia and early cancer in Barrett's esophagus.
Methods: Eight men and 2 women 43 to 84 years of age with short segments of Barrett's esophagus or traditional Barrett's esophagus and histologically proved low-grade (n = 4) and high-grade (n = 4) dysplasia or early adenocarcinoma (n = 2) were selected for this pilot study. For all patients thermal endoscopic destruction was conducted with a frequency-doubled neodymium:yttrium-aluminum-garnet (Nd:YAG) KTP laser system. Laser therapy was performed by means of the free-beam method with coaxial insufflation of gas. An average of 2.4 sessions per patient were required for ablation of the Barrett's mucosa.
Results: Two to three days after laser treatment the response of the ablated mucosa was assessed with endoscopy and biopsy. Samples taken showed fibrinoid necrosis of the mucosal layer. A complete response was obtained for all 10 patients. Replacement by normal squamous cell epithelium was induced in combination with acid suppression therapy of up to 80 mg omeprazole daily. No complications occurred. In two patients biopsy showed specialized mucosa beneath the restored squamous cell epithelial layer. Follow-up times were as long as 15 months (mean value 10.6 months).
Conclusions: KTP laser destruction of Barrett's esophagus induced mucosal regeneration with normal squamous cell epithelium in combination with acid suppression. Limitation of the depth of thermal destruction in Barrett's esophagus minimizes risk for perforation or stricture formation. KTP laser ablation of Barrett's esophagus seems to be feasible and safe in short segments of Barrett's esophagus with dysplasia or early cancer.
Comment in
- Ablation therapy for Barrett's esophagus: is it time to choose our weapons?
Lightdale CJ. Lightdale CJ. Gastrointest Endosc. 1999 Jan;49(1):122-5. doi: 10.1016/s0016-5107(99)70461-x. Gastrointest Endosc. 1999. PMID: 9869739 Review. No abstract available.
Similar articles
- Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients.
Overholt BF, Panjehpour M, Haydek JM. Overholt BF, et al. Gastrointest Endosc. 1999 Jan;49(1):1-7. doi: 10.1016/s0016-5107(99)70437-2. Gastrointest Endosc. 1999. PMID: 9869715 - Neodymium:yttrium-aluminum garnet contact laser ablation of Barrett's high grade dysplasia and early adenocarcinoma.
Weston AP, Sharma P. Weston AP, et al. Am J Gastroenterol. 2002 Dec;97(12):2998-3006. doi: 10.1111/j.1572-0241.2002.07117.x. Am J Gastroenterol. 2002. PMID: 12492182 - The diagnosis and management of Barrett's esophagus.
DeMeester SR, DeMeester TR. DeMeester SR, et al. Adv Surg. 1999;33:29-68. Adv Surg. 1999. PMID: 10572561 Review. - High power setting argon plasma coagulation for the eradication of Barrett's esophagus.
Pereira-Lima JC, Busnello JV, Saul C, Toneloto EB, Lopes CV, Rynkowski CB, Blaya C. Pereira-Lima JC, et al. Am J Gastroenterol. 2000 Jul;95(7):1661-8. doi: 10.1111/j.1572-0241.2000.02197.x. Am J Gastroenterol. 2000. PMID: 10925965 Clinical Trial. - AGA Clinical Practice Update on Endoscopic Treatment of Barrett's Esophagus With Dysplasia and/or Early Cancer: Expert Review.
Sharma P, Shaheen NJ, Katzka D, Bergman JJGHM. Sharma P, et al. Gastroenterology. 2020 Feb;158(3):760-769. doi: 10.1053/j.gastro.2019.09.051. Epub 2019 Nov 12. Gastroenterology. 2020. PMID: 31730766 Review.
Cited by
- The treatment of Barrett's esophagus.
Hoara P, Gindea C, Birla R, Mocanu A, Tavlas E, Constantinoiu S. Hoara P, et al. J Med Life. 2009 Jul-Sep;2(3):241-8. J Med Life. 2009. PMID: 20112466 Free PMC article. Review. - Barrett's Esophagus: A Review of Biology and Therapeutic Approaches.
Kountourakis P, Ajani JA, Davila M, Lee JH, Bhutani MS, Izzo JG. Kountourakis P, et al. Gastrointest Cancer Res. 2012 Mar;5(2):49-57. Gastrointest Cancer Res. 2012. PMID: 22690258 Free PMC article. - Limited resection for early adenocarcinoma in Barrett's esophagus.
Stein HJ, Feith M, Mueller J, Werner M, Siewert JR. Stein HJ, et al. Ann Surg. 2000 Dec;232(6):733-42. doi: 10.1097/00000658-200012000-00002. Ann Surg. 2000. PMID: 11088068 Free PMC article. - Ablative mucosectomy is the procedure of choice to prevent Barrett's cancer.
Fitzgerald RC. Fitzgerald RC. Gut. 2003 Jan;52(1):16-7. doi: 10.1136/gut.52.1.16. Gut. 2003. PMID: 12477752 Free PMC article. No abstract available. - Photodynamic therapy for dysplastic Barrett's oesophagus: a prospective, double blind, randomised, placebo controlled trial.
Ackroyd R, Brown NJ, Davis MF, Stephenson TJ, Marcus SL, Stoddard CJ, Johnson AG, Reed MW. Ackroyd R, et al. Gut. 2000 Nov;47(5):612-7. doi: 10.1136/gut.47.5.612. Gut. 2000. PMID: 11034574 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical